Celltrion is expanding its collaboration framework with promising bio and medical startups.
Celltrion said on the 10th that it has finalized the selection of four corporations to join the 4th class of the "2026 Seoul Bio Hub–Celltrion Open Innovation Program."
▲ AI-based protein antibody development platform company AINB ▲ GLP-1 derivative oral delivery formulation platform company Enbiocell ▲ Imitascience, which has disease modeling and drug evaluation technology based on biomimetic tissue ▲ Podotherapeutics, a patient-derived Organoid (PDO)–based precision medicine platform company.
The four corporations were ultimately chosen after a review by a judging panel that included external technology evaluators. These companies will receive tailored support by growth stage, including technology advancement and mentoring, as well as a review of joint research and commercialization possibilities with Celltrion.
A company representative said, "We will continue to expand points of cooperation with promising startups and work to contribute to the sustained growth of the domestic bio ecosystem."
The program was created to identify bio and medical startups with innovative technologies that can be linked to Celltrion's research and development needs and, in cooperation with Seoul Bio Hub, support technology advancement and the expansion of growth foundations. Through this, Celltrion plans to broaden the collaboration base of Korea's bio ecosystem.